Prescient Therapeutics Ltd has released a press release.
Appendix 4D and Half Year Financial Report
Earlier from Prescient Therapeutics
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- September Quarterly Updated and Appendix 4C